<DOC>
	<DOC>NCT00861601</DOC>
	<brief_summary>This is an open label, multi-centre, dose ranging study to assess efficacy, safety and pharmacokinetics of eltrombopag in thrombocytopenic subjects with chronic liver disease.</brief_summary>
	<brief_title>Phase 2, Pharmacokinetics Study of Eltrombopag in Japanese Thrombocytopenic Subjects With Chronic Liver Disease</brief_title>
	<detailed_description />
	<mesh_term>Liver Diseases</mesh_term>
	<criteria>Subject who agree to comply with protocol requirements and instructions and who provide signed and dated written informed consent. Male and female subjects, ≥20 years of age (at the time of informed consent) with chronic liver disease. ChildPugh score &lt;=9. A baseline platelet count &lt;50,000/mcL. A baseline serum sodium level &gt;130 mEq/L. Haemoglobin concentration &gt;8 g/dL, stable for at least 4 weeks. A female is eligible to enter and participate in the study if she is of: Nonchildbearing potential (i.e., physiologically incapable of becoming pregnant) including any female who: Has had a hysterectomy Has had a bilateral oophorectomy (ovariectomy) Has had a bilateral tubal ligation Is postmenopausal (demonstrate total cessation of menses for longer than one year) Childbearing potential, has a negative urine and/or serum pregnancy test at screening, and within the 24 hour period prior to the first dose of investigational product and uses one of the following acceptable methods of contraception: Complete abstinence from intercourse. Any intrauterine device (IUD) with a documented failure rate of less than 1% per year. Doublebarrier contraception (condom with spermicidal jelly, or diaphragm with spermicide). Male partner who is sterile (diagnosed by a qualified medical professional) prior to the female subject's study entry and is the sole sexual partner for that female. Oral contraceptive (combined). Subject has no physical limitation to ingest and retain oral medication. Subjects with known or suspected hypersensitivity, intolerance or allergy to any of the ingredients in eltrombopag tablets. Evidence of portal vein thrombosis on abdominal imaging (ultrasound with Doppler or appropriate magnetic resonance imaging/computed tomography (MRI/CT) imaging techniques) within 3 months before the start of the study. History of arterial or venous thrombosis (including BuddChiari Syndrome), AND ≥ two of the following risk factors: hereditary thrombophilic disorders (e.g. antithrombinIII (ATIII) deficiency, etc.) hormone replacement therapy systemic contraception therapy (containing oestrogen) smoking diabetes hypercholesterolemia medication for hypertension or cancer Human Immunodeficiency Virus (HIV) infection. History of drug/alcohol abuse or dependence within 1 year prior to screening. Any disease condition associated with current active World Health Organization (WHO) Grade 3 or 4 bleeding. Active infection requiring systemic antibiotic therapy. Pregnant, nursing mothers, women who may be pregnant, or women who plan to become pregnant during the time of study participation. Treatment with platelet transfusion within 2 weeks prior to Day 1. Treatment with interferon within 4 weeks prior to Day 1. Treatment with an investigational drug within 30 days or five halflives (whichever is longer) preceding the first dose of study medication. History of platelet agglutination abnormality. History of porphyria. Subjects who are deemed unsuitable for the study by the investigator (or subinvestigator).</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2011</verification_date>
</DOC>